WALTHAM, Mass.–(BUSINESS WIRE)– #ACR2026–Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.